Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate
- PMID: 20359847
- DOI: 10.1016/j.biopha.2009.06.014
Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate
Abstract
The aetiology of thalassemia major-induced osteoporosis is multifactorial. Up to now, bisphosphonates seem to be a promising therapy. Taurine is found in a high concentration in bone cells enhancing bone tissue formation and inhibiting bone loss. Recently we found a decrease taurine plasma level in children affected by osteogenesis imperfecta during neridronate (amino-bisphosphonate) therapy suggesting a possible interaction between pharmacological effect of this drug and taurine availability. On the basis of these results, we performed plasma and urine amino acid (AA) analysis in thalassemia major-induced osteoporosis before and after 12 months of neridronate treatment. Twelve patients, five males and seven females, aged from 20 to 29 years following a hypertransfusion treatment protocol were enrolled in the study. Patients were treated with neridronate infusion every one month (30 mg in 100ml of saline). Plasma and urine specimens for AA analysis, bone mineral density, bone mineral content and vertebral project area were examined at baseline (T0) and after 12 months of treatment (T12). A significant decrease was observed for plasma level and urinary excretion of taurine (T0 vs. T12=p<0.01) whereas bone mineral content and vertebral projection area showed a statistical significant increase (T0 vs. T12=p<0.05). These results and other experimental researches warrant further studies examining the long-term effect of taurine supplementation in association with neridronate treatment.
(c) 2009 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.Biomed Pharmacother. 2007 May;61(4):235-40. doi: 10.1016/j.biopha.2006.11.005. Epub 2006 Dec 29. Biomed Pharmacother. 2007. PMID: 17275249
-
Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:144-8. Pediatr Endocrinol Rev. 2008. PMID: 19337169 Clinical Trial.
-
Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.Ann Hematol. 2007 Jan;86(1):23-30. doi: 10.1007/s00277-006-0180-7. Epub 2006 Sep 30. Ann Hematol. 2007. PMID: 17013645 Clinical Trial.
-
Bisphosphonate treatment of pediatric bone disease.Pediatr Endocrinol Rev. 2005 Dec;3(2):87-96. Pediatr Endocrinol Rev. 2005. PMID: 16361982 Review.
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
Cited by
-
Investigation of taurine and aqueous garlic extract diet supplementation effect on the healing of rat osteoporotic fractures.Turk J Med Sci. 2023 Feb;53(1):29-39. doi: 10.55730/1300-0144.5555. Epub 2023 Feb 22. Turk J Med Sci. 2023. PMID: 36945935 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical